Research programme: matrix metalloproteinase-12 inhibitors - Pfizer
Latest Information Update: 31 Mar 2011
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Small molecules
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 31 Mar 2011 This programme is still in active development